Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A

US9273068B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Hervé Geneste · Schifferstadt, DE
• Michael Ochse · Wiesbaden, DE
• Karla Drescher · Ludwigshafen, DE
• Sean Colm Turner · Ludwigshafen, DE
• Berthold Behl · Ludwigshafen, DE
• Loic Laplanche · Ludwigshafen, DE
• Jurgen Dinges · Wadsworth, US
• Clarissa Jakob · North Chicago, US
• Lawrence A. Black · Libertyville, US

Key dates

• Filing date: Oct 29, 2012
• Grant date: Mar 1, 2016
• Expiry date: Aug 17, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.